BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

Androcur Effects on Quality of Life

Completed

Conditions: Prostate Cancer

Interventions: Drug: Cyproterone acetate (Androcur)

First Posted Date: 2009-05-27

Last Posted Date: 2010-04-13

Lead Sponsor: Bayer

Target Recruit Count: 245

Registration Number: NCT00908674

LEVITRA® 20mg Special Drug Use Investigation (Long-term)

Completed

Conditions: Erectile Dysfunction

Interventions: Drug: Vardenafil, (Levitra, BAY38-9456)

First Posted Date: 2009-05-27

Last Posted Date: 2014-12-15

Lead Sponsor: Bayer

Target Recruit Count: 1221

Registration Number: NCT00909233

Observational Study on the Safety and Tolerability of Gadobutrol (Gadovist) Among Filipino Patients in Magnetic Resonance Imaging

Completed

Conditions: Magnetic Resonance Imaging

Interventions: Drug: Gadobutrol (Gadovist, BAY86-4875)

First Posted Date: 2009-05-21

Last Posted Date: 2013-04-26

Lead Sponsor: Bayer

Target Recruit Count: 30

Registration Number: NCT00905879

Effects of Counseling on the Continuation Rates and Compliance for Newly Prescribed Oral Contraceptives (Yasmin® or Any Other Oral Contraceptives (OC)

Completed

Conditions: Contraception

Interventions: Drug: EE30/DRSP (Yasmin, BAY86-5131)
Drug: Any other OC

First Posted Date: 2009-05-20

Last Posted Date: 2012-03-07

Lead Sponsor: Bayer

Target Recruit Count: 5446

Registration Number: NCT00905684

Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma

Phase 3

Completed

Conditions: Carcinoma, Hepatocellular

Interventions: Drug: Sorafenib (Nexavar, BAY43-9006)
Drug: Erlotinib (Tarceva)
Drug: Placebo

First Posted Date: 2009-05-14

Last Posted Date: 2019-05-30

Lead Sponsor: Bayer

Target Recruit Count: 732

Registration Number: NCT00901901

Injection Management With Betaferon: Influence on Adherence, Patients Satisfaction and Health Related Outcomes (BETAPATH)

Completed

Conditions: Relapsing-Remitting Multiple Sclerosis

Interventions: Drug: Interferon beta-1b (Betaseron, BAY86-5046)

First Posted Date: 2009-05-14

Last Posted Date: 2015-07-17

Lead Sponsor: Bayer

Target Recruit Count: 702

Registration Number: NCT00902135

Transdermal Contraceptive Patch - Endometrial Effects Study

Phase 2

Completed

Conditions: Contraception

Interventions: Drug: Ethinylestradiol/Gestogene (BAY86-5016)

First Posted Date: 2009-05-11

Last Posted Date: 2014-11-26

Lead Sponsor: Bayer

Target Recruit Count: 92

Registration Number: NCT00896571

Patient Characteristics in Advanced Renal Cell Carcinoma and Daily Practice Treatment With Nexavar

Completed

Conditions: Carcinoma, Renal Cell
Carcinoma, Renal Cell (Advanced)

Interventions: Drug: Nexavar (Sorafenib, BAY43-9006)

First Posted Date: 2009-05-08

Last Posted Date: 2010-09-30

Lead Sponsor: Bayer

Target Recruit Count: 2840

Registration Number: NCT00895674

BEYOND Pilot Study

Phase 2

Completed

Conditions: Multiple Sclerosis
Relapsing-Remitting

Interventions: Drug: Betaseron (Interferon beta-1b, BAY86-5046)

First Posted Date: 2009-05-05

Last Posted Date: 2009-11-09

Lead Sponsor: Bayer

Target Recruit Count: 71

Registration Number: NCT00893217

Comparative Safety Study of New Sinecort Formulation Versus Positive Control

Phase 1

Completed

Conditions: Healthy

Interventions: Device: Untreated skin under application chamber
Drug: Dexpanthenol (Sinecort, BAY81-2996)
Drug: Positive control, Na-laurylsulfat-solution

First Posted Date: 2009-04-22

Last Posted Date: 2014-06-23

Lead Sponsor: Bayer

Target Recruit Count: 33

Registration Number: NCT00885937

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy